MRNA is trading 5.1% up at $48.04 as the stock stages a relief bounce following yesterday's rate-driven biotech selloff.
- Recent weakness was tied to surging Treasury yields pressuring growth and biotech names rather than company-specific negatives.
- Today's move reflects a sector-wide recovery as risk appetite stabilizes following Tuesday's sharp move in bond yields.